healthcare · stock-sale · portfolio-rebalance
Ill-Timed Divestment: Rep. Cisneros Misses 25% Rally in Revvity
The California Democrat sold up to $50,000 of the life sciences stock right before it embarked on a sharp upward run.
2026-10-14 — Gilbert Cisneros · RVTY
Key facts
- Rep. Gilbert Cisneros sold between $15,001 and $50,000 of Revvity (RVTY) on September 9, 2026.
- Since the transaction, Revvity stock has surged approximately 25%, rising from $123.85 to $154.38.
- The sale was executed as a same-day swap with a purchase of NXP Semiconductors (NXPI) in the same dollar range.
- Cisneros serves on the Armed Services and Small Business committees, which have no regulatory oversight over Revvity's primary healthcare markets.
On September 9, 2026, Rep. Gilbert Cisneros (D-Ga.) sold between $15,001 and $50,000 of Revvity, Inc. (NYSE: RVTY), a life sciences solution and analytical instruments provider. Since the sale, which was executed at $123.85, the stock has rallied 24.6% to close at $154.38.
Our analysis scored the trade a low 19/100, suggesting the transaction was a routine portfolio adjustment rather than a move driven by non-public information. On the same day as the Revvity sale, Cisneros executed a purchase of NXP Semiconductors (NXPI) in the exact same range of $15,001 to $50,000. This same-day swap, combined with his high-frequency trading profile of nearly 29 trades per month, points to an automated or advisor-managed portfolio rebalancing.
Cisneros had built up his position in the Waltham, Massachusetts-based Revvity through seven consecutive purchases between May 2025 and May 2026. He began a phased exit in early September 2026, making smaller sales of up to $15,000 on September 3 and September 4 before the larger September 9 divestment.
Cisneros serves on the House Committee on Armed Services and the Committee on Small Business. Neither committee has regulatory oversight or appropriations authority over the Food and Drug Administration (FDA) or the Department of Health and Human Services (HHS), which serve as Revvity's primary regulators. While Revvity holds minor maintenance and repair service contracts with the Department of Defense, these represent a peripheral fraction of the company's core business.
Members of Congress are required by the STOCK Act to disclose trades within 45 days, and disclosed amounts are reported in ranges. Cisneros disclosed the transaction on October 12, 2026, representing a 33-day filing lag.
While Cisneros was exiting, company insiders were also active. Several Revvity executives disclosed stock sales shortly after Cisneros's trade, including insider transactions in mid-to-late September. These trades followed a major corporate update on August 4, 2026, when Revvity announced it had raised its full-year guidance and entered a definitive agreement to divest its China immunodiagnostics business.
Cisneros's exit may have been part of an orderly portfolio rebalance, but the timing proved highly expensive.